A late-stage hit with its respiratory syncytial virus jab would be a huge validation for the group’s new focus.
After a long wait the groups’ jab delivers mediocre efficacy.
A look at the past week’s Covid winners and losers finds Pfizer, unusually, among the latter.
The group’s Covid vaccine, as well as Sanofi and Glaxosmithkline’s jab, might not reach Europe for some time.
Drug makers and regulators take aim at Omicron.